Annual Cash & Cash Equivalents
$3.02 B
-$979.46 M-24.46%
March 31, 2024
Summary
- As of February 7, 2025, TAK annual cash & cash equivalents is $3.02 billion, with the most recent change of -$979.46 million (-24.46%) on March 31, 2024.
- During the last 3 years, TAK annual cash & cash equivalents has fallen by -$5.73 billion (-65.47%).
- TAK annual cash & cash equivalents is now -78.35% below its all-time high of $13.97 billion, reached on March 31, 2007.
Performance
TAK Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$3.15 B
-$2.87 B-47.69%
December 1, 2024
Summary
- As of February 7, 2025, TAK quarterly cash and cash equivalents is $3.15 billion, with the most recent change of -$2.87 billion (-47.69%) on December 1, 2024.
- Over the past year, TAK quarterly cash and cash equivalents has dropped by -$2.87 billion (-47.69%).
- TAK quarterly cash and cash equivalents is now -70.00% below its all-time high of $10.49 billion, reached on March 31, 2011.
Performance
TAK Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TAK Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -24.5% | -47.7% |
| 3 y3 years | -65.5% | -21.4% |
| 5 y5 years | -52.2% | -64.1% |
TAK Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -65.5% | at low | -54.8% | +53.9% |
| 5 y | 5-year | -65.5% | at low | -64.1% | +53.9% |
| alltime | all time | -78.3% | +30.5% | -70.0% | +53.9% |
Takeda Pharmaceutical Company Limited Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $3.15 B(-47.7%) |
| Sep 2024 | - | $6.01 B(+20.4%) |
| Jun 2024 | - | $5.00 B(+65.2%) |
| Mar 2024 | $3.02 B(-24.5%) | $3.02 B(+47.9%) |
| Dec 2023 | - | $2.04 B(-4.0%) |
| Sep 2023 | - | $2.13 B(-2.6%) |
| Jun 2023 | - | $2.18 B(-45.4%) |
| Mar 2023 | $4.00 B(-42.5%) | $4.00 B(-23.4%) |
| Dec 2022 | - | $5.23 B(-5.4%) |
| Sep 2022 | - | $5.52 B(+16.8%) |
| Jun 2022 | - | $4.73 B(-32.1%) |
| Mar 2022 | $6.96 B(-20.5%) | $6.96 B(+10.6%) |
| Dec 2021 | - | $6.29 B(+15.9%) |
| Sep 2021 | - | $5.43 B(-8.3%) |
| Jun 2021 | - | $5.92 B(-32.4%) |
| Mar 2021 | $8.76 B(+48.5%) | $8.76 B(+46.3%) |
| Dec 2020 | - | $5.99 B(+0.3%) |
| Sep 2020 | - | $5.97 B(+8.9%) |
| Jun 2020 | - | $5.48 B(-7.1%) |
| Mar 2020 | $5.90 B(-6.8%) | $5.90 B(+13.1%) |
| Dec 2019 | - | $5.22 B(+3.7%) |
| Sep 2019 | - | $5.03 B(-8.5%) |
| Jun 2019 | - | $5.50 B(-13.1%) |
| Mar 2019 | $6.33 B(+128.5%) | $6.33 B(+134.6%) |
| Dec 2018 | - | $2.70 B(-3.2%) |
| Sep 2018 | - | $2.79 B(+33.2%) |
| Jun 2018 | - | $2.09 B(-24.4%) |
| Mar 2018 | $2.77 B(-3.0%) | $2.77 B(-29.0%) |
| Dec 2017 | - | $3.91 B(+2.0%) |
| Sep 2017 | - | $3.83 B(-0.7%) |
| Jun 2017 | - | $3.86 B(+35.1%) |
| Mar 2017 | $2.86 B(-28.9%) | $2.86 B(-40.6%) |
| Dec 2016 | - | $4.81 B(-21.4%) |
| Sep 2016 | - | $6.12 B(+8.1%) |
| Jun 2016 | - | $5.66 B(+40.9%) |
| Mar 2016 | $4.02 B | $4.02 B(-13.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | - | $4.66 B(-8.2%) |
| Sep 2015 | - | $5.07 B(+8.0%) |
| Jun 2015 | - | $4.70 B(-13.5%) |
| Mar 2015 | $5.43 B(-16.1%) | $5.43 B(-16.9%) |
| Dec 2014 | - | $6.54 B(+5.0%) |
| Sep 2014 | - | $6.23 B(+1.4%) |
| Jun 2014 | - | $6.14 B(-5.1%) |
| Mar 2014 | $6.47 B(+11.7%) | $6.47 B(+53.9%) |
| Dec 2013 | - | $4.21 B(+16.7%) |
| Sep 2013 | - | $3.60 B(+33.0%) |
| Jun 2013 | - | $2.71 B(-53.2%) |
| Mar 2013 | $5.79 B(+5.0%) | $5.79 B(+90.0%) |
| Dec 2012 | - | $3.05 B(+11.4%) |
| Sep 2012 | - | $2.74 B(+5.8%) |
| Jun 2012 | - | $2.59 B(-53.1%) |
| Mar 2012 | $5.52 B(-47.4%) | $5.52 B(+122.6%) |
| Dec 2011 | - | $2.48 B(-23.4%) |
| Sep 2011 | - | $3.24 B(+36.7%) |
| Jun 2011 | - | $2.37 B(-77.4%) |
| Mar 2011 | $10.49 B(+268.2%) | $10.49 B(+342.4%) |
| Dec 2010 | - | $2.37 B(-10.5%) |
| Sep 2010 | - | $2.65 B(+2.0%) |
| Jun 2010 | - | $2.60 B(-8.9%) |
| Mar 2010 | $2.85 B(+22.9%) | $2.85 B(-3.7%) |
| Dec 2009 | - | $2.96 B(+2.0%) |
| Sep 2009 | - | $2.90 B(+25.1%) |
| Mar 2009 | $2.32 B(-3.3%) | $2.32 B(-5.5%) |
| Dec 2008 | - | $2.45 B |
| Mar 2008 | $2.40 B(-82.8%) | - |
| Mar 2007 | $13.97 B(+1.2%) | - |
| Mar 2006 | $13.81 B(+17.0%) | - |
| Mar 2005 | $11.80 B(+14.2%) | - |
| Mar 2004 | $10.33 B(+19.1%) | - |
| Mar 2003 | $8.67 B(+65.0%) | - |
| Mar 2002 | $5.25 B(+4.4%) | - |
| Mar 2001 | $5.03 B | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual cash & cash equivalents year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly cash and cash equivalents year-on-year change?
What is Takeda Pharmaceutical Company Limited annual cash & cash equivalents?
The current annual cash & cash equivalents of TAK is $3.02 B
What is the all time high annual cash & cash equivalents for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual cash & cash equivalents is $13.97 B
What is Takeda Pharmaceutical Company Limited annual cash & cash equivalents year-on-year change?
Over the past year, TAK annual cash & cash equivalents has changed by -$979.46 M (-24.46%)
What is Takeda Pharmaceutical Company Limited quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of TAK is $3.15 B
What is the all time high quarterly cash and cash equivalents for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly cash and cash equivalents is $10.49 B
What is Takeda Pharmaceutical Company Limited quarterly cash and cash equivalents year-on-year change?
Over the past year, TAK quarterly cash and cash equivalents has changed by -$2.87 B (-47.69%)